Original from: 360dx

Omics firm Sapient said Wednesday that it has partnered with Alamar Biosciences to provide proteomics services using Alamar's NULISA multiplexed immunoassay platform.

San Diego-based Sapient will be an Alamar certified service provider for the NULISAseq Inflammation panel, which targets more than 250 cytokines and chemokines, and the NULISAseq CNS Disease panel, which measures more than 120 neurodegeneration and neuroinflammatory markers.

Financial and other terms of the deal were not disclosed.

Sapient will also offer development of custom proteomic assays using Alamar's technology and will work with Alamar to offer its assays under regulated guidance including CAP/CLIA and GCLP.

Sapient said Alamar's offerings will complement its existing mass spectrometry-based proteomics approaches.

"NULISA-based inflammatory profiling is a perfect complement to our established proteomics, metabolomics, lipidomics, and RNAseq approaches," Sapient CEO Jonathan Usuka said in a statement. "Collectively these multiomic based measures allow us to fully interrogate the dynamic biomarkers of human health, disease, and drug response for our clients, as well as to identify promising drug targets."

Source: Sapient Partnering With Alamar Bio to Offer Proteomics Services on NULISA Platform